Status:
RECRUITING
Danish Elder Lymphoma Patient Hematopoietic Investigation
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Aalborg University Hospital
Odense University Hospital
Conditions:
Lymphoma
Chemotherapy-induced Neutropenia
Eligibility:
All Genders
60+ years
Brief Summary
Every year approximately 300 Danish patients die from lymphoma. The median age at diagnosis is 70 years. Lymphoma can be efficiently treated with chemotherapy, and potentially cured. However, sufficie...
Detailed Description
DELPHI is prospective nationwide observational study investigating blood mutations in patients with lymphoma. Inclusion criteria: * Diagnosis of B-cell Non-Hodgkin lymphoma * In need of systemic tre...
Eligibility Criteria
Inclusion
- Diagnosis of r/r B-cell Non-Hodgkin lymphoma
- In need of systemic treatment with second (2.) or higher line of active therapy for lymphoma
- 60 years of age or older (no age maximum)
Exclusion
- Unable to give written consent
- Non-Danish citizens
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2035
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05245487
Start Date
January 1 2022
End Date
January 1 2035
Last Update
December 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Hematology, Rigshospitalet
Copenhagen, Denmark